

WELCOME

Addiction Medicine ECHO Clinic



The session will begin promptly at 12 pm.



Please mute the audio on your device.



Sessions take place Thursday on the 2^{cd} and 4th week of the month.



Please connect your camera.

Need technical assistance? Call [907.729.2622](tel:907.729.2622) or text your phone number into the chat.



ALASKA NATIVE
TRIBAL HEALTH
CONSORTIUM



Foundation for
Opioid Response Efforts

Recording

We will record the **didactic portion** of every session. After the session, the didactic portion of this clinic will be available on the ANTHC Addiction Medicine ECHO page.


By participating in this clinic you are consenting to be recorded.

If you do not wish to be recorded, please email behavioralhealth@anthc.org at least one week prior to the ECHO Clinic you plan to attend.

Some Helpful Tips

- ▶ Please mute microphone when not speaking
- ▶ Use chat function
- ▶ Position webcam effectively
- ▶ Test both audio & video

Need technical assistance? Use the chat function or call 907-317-5209



ANTHC Clinical ECHO Series

Approved Provider Statements:

ANTHC is accredited by the Washington State Medical Association to provide continuing medical education for physicians.


ANTHC is approved as a provider of nursing continuing professional development by the Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

AKPhA is accredited by the Accreditation Council for Pharmacy Education as a provider of Continuing Pharmacy Education.

Contact Hours:

ANTHC designates this Live/Virtual Activity for a maximum of 12 AMA PRA Category 1 Credit(s)™ for the entire series, provided in 1 credit/session certificates. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANTHC designates this activity as meeting the criteria for one nursing contact hour credit for each hour of participation up to a maximum of 12 hour(s) for the entire series, provided in 1 contact hour certificates/session attended.

 The Alaska Pharmacists Association (AKPhA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Through a Joint Providership, ANTHC and AKPhA designates this pharmacist activity for a maximum of 1 hours(s) per session. To receive CE credit, participants must be included in attendance record of facilitator/virtual format moderator with the NABP e-profile number including MM/DD birthdate, and complete the evaluation or post session survey. CPE credit will be posted to the online CPE Monitor System within 60 days of activity completion. CPE credit is offered at no charge to ANTHC/SCF employees and AKPhA members. Fees may apply to participants not affiliated with either organization.

Approved for 1 CHAP CE

Conflict of Interest Disclosures:

None of the presenters and planners for this educational activity have any relevant relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Requirements for Successful Completion:



To receive CE credit be sure you are included in attendance record as directed by the facilitator/session moderator, and complete the course evaluation or post session survey via this link: <https://forms.gle/QhwCeGTf4zLNwpBX7>

For more information contact Jennifer Fielder at jfielder@anthc.org or (907) 729-1387

Introductions

Addiction Medicine ECHO

- Please introduce yourself in the chat :
 - Name
 - Location
 - Profession/Credentials
 - *Note:* The chat will be saved as our attendance record for continuing education credits.



Conflict of Interest Disclosure

- ▶ No COI to disclose

Objectives

- ▶ Participants will be able to describe recent data trends of alcohol misuse in Alaska
- ▶ Participants will be able to explain short and long-term effects of alcohol misuse on the brain

Quick Facts - mortality


- ▶ For the 2014-2018 period, “the Alaska Native alcohol abuse mortality rate, both sexes combined, was 8.0 times the U.S. all races rate.”
- ▶ “Alaska Native females had an alcohol abuse mortality rate 12.4 times the U.S. all races female rate.”
- ▶ “Alaska Native males had an alcohol abuse mortality rate 6.4 times the rate for U.S. all races males.”
- ▶ “Alcohol abuse accounted for 4.9% (n=111) of all excess death among Alaska Native people, both sexes combined.”

Quick Facts - treatment

- ▶ Nationally, about 7% of those with AUD were treated in the past year.
- ▶ Nationally, less than 4% of people with AUD were prescribed medication.
- ▶ People are more likely to seek treatment from primary care doctors for health issues related to AUD than to seek care specifically for AUD.
- ▶ For people age 26 and over, the occurrence of AUD was about the same, between 5% and 6%, for American Indian/Alaska Native people and the overall U.S. population.


(1) SAMHSA, Center for Behavioral Health Statistics and Quality. 2019 National Survey on Drug Use and Health (NSDUH-2019-DS0001). Public data set. <https://www.datafiles.samhsa.gov/study-dataset/national-survey-drug-use....> Accessed December 8, 2020. (2) (3) Rehm, J.; Anderson, P.; Manthey, J.; et al. Alcohol use disorders in primary health care: What do we know and where do we go? *Alcohol and Alcoholism* 51(4):422-427, 2016. PMID: 2657460 (4) O'Connor, P.G.; Nyquist, J.G.; and McLellan, A.T. Integrating addiction medicine into graduate medical education in primary care: The time has come. *Annals of Internal Medicine* 154(1):56-59, 2011. PMID: 21200039

Number of treatment episodes, by substance, Alaska statewide data, Treatment Episode Dataset (SAMHSA), 2019




Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Based on administrative data reported by states to TEDS through July 1, 2020.


Number of alcohol only treatment episodes and alcohol with secondary drug treatment episodes, Alaska statewide data, Treatment Episode Dataset (SAMHSA), 2015-2019



Alcohol only and alcohol with secondary drug treatment episodes as a percent of all substance-related treatment episodes, Alaska statewide data, Treatment Episode Dataset (SAMHSA), 2015-2019




Alcohol abuse as a leading cause of Years of Potential Life Lost (YPLL) before age 75 among Alaska Native People, 2014-2018




Alaska Native Epidemiology Center, Alaska Native Tribal Health Consortium, Alaska Native Mortality Report, 4th Edition, 1980-2018 (May 2021). Data: State of Alaska Department of Health and Social Services, Health Analytics and Vital Records.

Alcohol abuse as a percent of total Years of Potential Life Lost (YPLL) before age 75 among Alaska Native People, 2014-2018




Trends in age-adjusted mortality rates per 100,000 among Alaska Native people statewide, 1980-2018




Alaska Native Epidemiology Center, Alaska Native Tribal Health Consortium, Alaska Native Mortality Report, 4th Edition, 1980-2018 (May 2021). Data: State of Alaska Department of Health and Social Services, Health Analytics and Vital Records.

Alcohol use disorder among American Indians/Alaska Natives, U.S. national data, by age group and year (NSDUH), 2015-2019



*Estimate not shown due to low precision

Alcohol use disorder among American Indians/Alaska Natives and all races combined, U.S. national data, by age group and year (NSDUH), 2019




Effects - Short-term

Pathways

- ▶ Dopamine
- ▶ Serotonin
- ▶ γ -amino butyric acid (GABA)

Conditions/Structures

- ▶ Occipital, temporal, parietal lobes
- ▶ Hippocampus - memory impairment
- ▶ Alcohol poisoning



Effects - Long-term


Pathways

- ▶ Dopamine
- ▶ Serotonin
- ▶ γ -amino butyric acid (GABA)

Conditions/structures

- ▶ Overall brain volume reduction, white matter atrophy
- ▶ Hippocampus - reduced volume, memory impairment
- ▶ Hepatic encephalopathy
- ▶ Cerebellum - structural changes, damage, movement
- ▶ Frontal lobe - motor cortex, executive, speech production, emotion, urges
- ▶ Corpus callosum - atrophy
- ▶ Wernicke-Korsakoff syndrome (Wernicke's encephalopathy, Korsakoff's syndrome)

Dopamine Pathways



Functions

- Reward (motivation)
- Pleasure, euphoria
- Motor function (fine tuning)
- Compulsion
- Perseveration

Functions

- Mood
- Memory processing
- Sleep
- Cognition

References

- ▶ Alaska Native Epidemiology Center, Alaska Native Tribal Health Consortium, Alaska Native Mortality Report 4th Edition 1980-2018, Anchorage, AK.
- ▶ Alcohol Alert: Number 63: Alcohol's Damaging Effect on the Brain: NIH: National Institute on Alcohol Abuse and Alcoholism. <http://pubs.niaaa.nih.gov/publications/aa63/aa63.htm>.
- ▶ Banerjee N. (2014). Neurotransmitters in alcoholism: A review of neurobiological and genetic studies. *Indian Journal of Human Genetics*, 20(1), 20-31. <https://doi.org/10.4103/0971-6866.132750>
- ▶ Butterworth, R. Hepatic encephalopathy—A serious complication of alcoholic liver disease. *Alcohol Research & Health*. 2003;27(2): 143-145.
- ▶ Crews F. T. (2008). Alcohol-related neurodegeneration and recovery: mechanisms from animal models. *Alcohol Research & Health*, 31(4), 377-388.
- ▶ Fein, G., Shimotsu, R., Chu, R., & Barakos, J. (2009). Parietal gray matter volume loss is related to spatial processing deficits in long-term abstinent alcoholic men. *Alcoholism, Clinical and Experimental Research*, 33(10), 1806-1814. <https://doi.org/10.1111/j.1530-0277.2009.01019.x>
- ▶ Langlais P. J. (1995). Alcohol-related thiamine deficiency: Impact on cognitive and memory functioning. *Alcohol Health and Research World*, 19(2), 113-121.
- ▶ Lovinger D. M. (1997). Serotonin's role in alcohol's effects on the brain. *Alcohol Health and Research World*, 21(2), 114-120.
- ▶ Mark, T.L.; Kassed, C.A.; Vandivort-Warren, R.; et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. *Drug and Alcohol Dependence* 99(1-3):345-349, 2009. PMID: 18819759 O'Connor, P.G.; Nyquist, J.G.; and McLellan, A.T. Integrating addiction medicine into graduate medical education in primary care: The time has come. *Annals of Internal Medicine* 154(1):56-59, 2011. PMID: 21200039
- ▶ Oscar-Berman, M. & Marinkovic, K. (2003). Alcoholism and the brain: An overview. *Alcohol Research & Health*, 27(2): 125-133. <http://pubs.niaaa.nih.gov/publications/arh27-2/125-133.htm>.
- ▶ Preedy, V. (Ed) (2019). Neuroscience of alcohol: Mechanisms and treatment. Elsevier, Amsterdam, NL.
- ▶ Rehm, J.; Anderson, P.; Manthey, J.; et al. Alcohol use disorders in primary health care: What do we know and where do we go? *Alcohol and Alcoholism* 51(4):422-427, 2016. Sullivan, E., Harris, A., Pfefferbaum, M.D. (2010). Alcohol's effects on the brain and behavior. *Alcohol Research and Health*, 33(1-2): 127-143.
- ▶ Sullivan, E., Marsh L. (2003). Hippocampal volume deficits in alcoholic Korsakoff's syndrome. *Neurology*, Dec 23;61(12):1716-9. doi: 10.1212/01.wnl.0000098940.31882.bb. PMID: 14694035.
- ▶ Sullivan, E. V., Rosenbloom, M. J., Deshmukh, A., Desmond, J. E., & Pfefferbaum, A. (1995). Alcohol and the Cerebellum: Effects on Balance, Motor Coordination, and Cognition. *Alcohol Health and Research World*, 19(2), 138-141.
- ▶ Topiwala, A., Allan, C. L., Valkanova, V., Zsoldos, E., Filippini, N., Sexton, C., Mahmood, A., Fooks, P., Singh-Manoux, A., Mackay, C. E., Kivimäki, M., & Ebmeier, K. P. (2017). Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. *BMJ (Clinical research ed.)*, 357, j2353. <https://doi.org/10.1136/bmj.j2353>.
- ▶ Vasan S, Kumar A. Wernicke Encephalopathy. [Updated 2020 Nov 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470344/>

Case Presentation

Project ECHO's goal is to protect patient privacy

- ▶ To help Project ECHO accomplish that goal, please only display or say information that doesn't identify a patient or that cannot be linked to a patient.
- ▶ **References: For a complete list of protected information under HIPAA, please visit www.hipaa.com**

Thank you for joining us today.
We appreciate your participation and hope
to see you at the **NEXT ECHO Session:**
July 22, 2021 from 12pm -1 PM

You will be receiving a follow up survey that we hope you will complete to help us improve. If you are requesting continuing education credits, you will be required to complete the survey to receive your CMEs.

